- Home
- IBG vs IMMX Comparison
IBG vs IMMX Comparison
Compare IBG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- IMMX
- Stock Information
- Founded
- IBG 2018
- IMMX 2014
- Country
- IBG Australia
- IMMX United States
- Employees
- IBG N/A
- IMMX N/A
- Industry
- IBG Beverages (Production/Distribution)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- IBG Consumer Staples
- IMMX Health Care
- Exchange
- IBG Nasdaq
- IMMX Nasdaq
- Market Cap
- IBG 75.7M
- IMMX 82.6M
- IPO Year
- IBG 2024
- IMMX 2021
- Fundamental
- Price
- IBG $3.38
- IMMX $3.72
- Analyst Decision
- IBG Strong Buy
- IMMX Strong Buy
- Analyst Count
- IBG 1
- IMMX 1
- Target Price
- IBG N/A
- IMMX $8.00
- AVG Volume (30 Days)
- IBG 1.4M
- IMMX 797.4K
- Earning Date
- IBG 11-15-2025
- IMMX 11-07-2025
- Dividend Yield
- IBG N/A
- IMMX N/A
- EPS Growth
- IBG N/A
- IMMX N/A
- EPS
- IBG N/A
- IMMX N/A
- Revenue
- IBG $2,931,243.00
- IMMX N/A
- Revenue This Year
- IBG N/A
- IMMX N/A
- Revenue Next Year
- IBG N/A
- IMMX N/A
- P/E Ratio
- IBG N/A
- IMMX N/A
- Revenue Growth
- IBG N/A
- IMMX N/A
- 52 Week Low
- IBG $1.48
- IMMX $1.34
- 52 Week High
- IBG $9.85
- IMMX $4.00
- Technical
- Relative Strength Index (RSI)
- IBG 52.82
- IMMX 72.85
- Support Level
- IBG $3.61
- IMMX $2.31
- Resistance Level
- IBG $4.10
- IMMX $4.00
- Average True Range (ATR)
- IBG 0.44
- IMMX 0.33
- MACD
- IBG -0.11
- IMMX 0.11
- Stochastic Oscillator
- IBG 22.39
- IMMX 83.43
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.